enetic testing and implantable cardioverter-defibrillator use. Unless addressed, these gaps will likely widen as we move towards precision-medicine-based care of individuals with hypertrophic cardiomyopathy. The expense of clinical trials mandates new strategies to efficiently generate evidence and test novel therapies. In this context, we designed a decentralized, patient-centered randomized clinical trial leveraging mobile technologies, rather than in-person site visits, to test the efficacy of 12 weeks of canagliflozin for the treatment of heart failure, regardless of ejection fraction or diabetes status, on the reduction of heart failure symptoms. One thousand nine hundred patients will be enrolled with a medical record-confirmed diagnosis of heart failure, stratified by reduced (≤40%) or preserved (>40%) ejection fraction and randomized 11 to 100 mg daily of canagliflozin or matching placebo. The primary outcome will be the 12-week change in the total symptom score of the Kansas City Cardiomyopathy Questionnaire. Secondary outcomes will be daily step count and other scales of the Kansas City Cardiomyopathy Questionnaire. The trial is currently enrolling, even in the era of the coronavirus disease 20nt-reported outcomes as the primary clinical end point of the trial. Registration URL https//www.clinicaltrials.gov; Unique identifier NCT04252287.[Figure see text].Aim This paper reports on a study to assess institutional readiness (IR) of UK National Health Service sites that form part of the Northern Alliance Advanced Therapy Treatment Centre to deliver advanced therapy medicinal products (ATMPs). The paper discusses the development of an assessment tool to support self-assessment of IR in healthcare institutions. Methods The tool utilized criteria developed by clinicians to self-assess IR to deliver four classes of ATMP over a series of time points. Each assessment was independently analyzed and validated by independent expert groups. Results & conclusion The collated results indicated an overall trend toward IR for all classes of ATMP. The study highlighted areas where IR is evidenced, areas where work is ongoing and areas where further work is required to achieve IR. The study also facilitated validation of the IR assessment tool.Here we report on the genomic sequence and annotation for Pantoea ananatis OC5a, a strain that was isolated from an onion bulb grown in New York and that is pathogenic to onions, causing center rot of onion. OC5a is the first P. ananatis strain pathogenic to onions from New York to be completely assembled and sequenced. Having been assembled using long PacBio reads and high-fidelity Illumina reads, this genome is closed, complete, and of high-quality.The phloem-limited 'Candidatus Liberibacter asiaticus' (Las) causes huanglongbing (HLB), a destructive citrus disease. Graft-inoculated potted plants were used to assess Las speed of movement in phloem in greenhouse (GH), and the impacts of temperature on plant colonization in growth chambers (GC) experiments. For assessment of Las speed, plants were inoculated at the main stem and assessed over time by qPCR or symptom at various distances from the inoculum. For colonization, the plants were inoculated in one of two opposite top branches, were maintained at 8 to 20, 18 to 30 or 24 to 38ºC daily range, and assessed by qPCR of samples taken from non-inoculated shoots. For all experiments, frequencies of Las-positive sites were submitted to ANOVA and binomial GLM and logistic regression analysis. Probabilities of detecting Las in GH plants were functions of time and distance from the inoculation site, which resulted in 2.9 and 3.8 cm day-1 average speed of movement. In GC, the temperature impacted plant colonization by Las, new shoot emission and symptom expression. After a 7-month exposure time, Las was absent in all new shoot in the cooler environment (avg 3 per plant), and present in 70% at the milder (6 shoots, severe symptoms) and 25% in the warmer (8 shoots, no visible symptoms) environments. Temperature of 25.7ºC was the optimum condition for plant colonization. This explains the higher impact and incidence of HLB during the winter months or regions of milder climates in Brazil.Aim To better predict the survival of cervical squamous cell carcinoma (CESC) patients, we aimed to construct a signature according to different immune infiltration. https://www.selleckchem.com/products/torin-1.html Methods We downloaded the RNA sequences of CESC patients from the Cancer Genome Atlas database. By using single-sample gene set enrichment analysis, we separated the samples into high- and low-immunity groups. Then we separated the samples into training and testing datasets and performed the following analyses univariate, least absolute shrinkage and selection operator analysis, multivariate Cox regression analyses and weighted gene coexpression network analysis using R software. Gene ontology and Kyoto Encyclopedia of Genes and Genomes studies were performed using the Database for Annotation, Visualization and Integrated Discovery website. Results & conclusion We finally identified a signature with three mRNAs and two lncRNAs ADGRG5, HSH2D, ZMAT4, RBAKDN and LINC00200. In short, our study constructed an mRNA-lncRNA signature related to immune infiltration to better predict the survival of CESC patients.Prostate-specific membrane antigen (PSMA) PET/CT is a novel imaging technique for the detection and staging of either primary or recurrent prostate cancer. Early studies demonstrated its improved sensitivity and specificity over and in combination with other currently employed imaging techniques, such as multiparametric MRI, bone scan, PET and CT. However, the lack of strength and confidence in these studies has meant incorporation of PSMA PET/CT into clinical guidelines and practice has been limited to date. In response, a number of high-quality prospective studies have recently emerged and reflect exciting results seen in preceding publications. Here we recount some of the key earlier publications, report results from the latest studies and look to the future discussing some of the eagerly awaited ongoing clinical trials.